Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 7/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104478 | 0.88 | PDE4B (0.40) | SLC9A1ERN1KDM4EALDH1A1PTPN1 | |
| SCHEMBL3112770 | 0.84 | ERN1 (0.45) | SLC9A1ERN1KDM4EALDH1A1ESR1 | |
| SCHEMBL3102519 | 0.81 | NOTUM (0.42) | SLC9A1ERN1KDM4EALDH1A1PTPN1 | |
| SCHEMBL3107575 | 0.80 | ALDH1A1 (0.46) | ERN1KDM4EALDH1A1 | |
| SCHEMBL3100344 | 0.79 | ERN1 (0.34) | SLC9A1ERN1KDM4EALDH1A1PTPN1 | |
| SCHEMBL3102505 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1ESR1PTGS2LMNA | |
| SCHEMBL3037013 | 0.76 | KDM4E (0.56) | SLC9A1KDM4EALDH1A1PTPN1ESR1 | |
| SCHEMBL3089847 | 0.75 | GABRP (0.46) | SLC9A1 | |
| SCHEMBL3106956 | 0.74 | ERN1 (0.55) | ERN1KDM4EALDH1A1POLHPTGS1 | |
| SCHEMBL6862609 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1PDE3BPDE3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | SLC9A1 409/4885ERN1 1620/4885KDM4E 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.